| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 41 | 2022 | 65 | 5.000 |
Why?
|
| Pancreatic Neoplasms | 46 | 2023 | 343 | 4.110 |
Why?
|
| Pancreatitis, Acute Necrotizing | 23 | 2022 | 24 | 3.570 |
Why?
|
| Pancreatectomy | 36 | 2023 | 103 | 3.340 |
Why?
|
| Carcinoma, Pancreatic Ductal | 20 | 2023 | 113 | 2.090 |
Why?
|
| Postoperative Complications | 26 | 2023 | 1279 | 1.380 |
Why?
|
| Laparoscopy | 13 | 2021 | 494 | 1.250 |
Why?
|
| Pancreatic Ducts | 11 | 2020 | 30 | 1.240 |
Why?
|
| Adenocarcinoma | 15 | 2022 | 350 | 1.220 |
Why?
|
| Drainage | 15 | 2022 | 154 | 1.070 |
Why?
|
| Retrospective Studies | 76 | 2023 | 6620 | 1.040 |
Why?
|
| Pancreatic Fistula | 10 | 2021 | 18 | 1.010 |
Why?
|
| Adenocarcinoma, Mucinous | 9 | 2019 | 32 | 0.950 |
Why?
|
| Intestinal Fistula | 3 | 2020 | 11 | 0.850 |
Why?
|
| Middle Aged | 89 | 2022 | 17659 | 0.830 |
Why?
|
| Duodenal Diseases | 2 | 2020 | 15 | 0.820 |
Why?
|
| Sphincter of Oddi Dysfunction | 3 | 2023 | 3 | 0.780 |
Why?
|
| Pancreatic Diseases | 7 | 2015 | 38 | 0.770 |
Why?
|
| Mesenteric Veins | 2 | 2020 | 11 | 0.770 |
Why?
|
| Humans | 138 | 2023 | 63535 | 0.760 |
Why?
|
| Female | 111 | 2022 | 32947 | 0.740 |
Why?
|
| Pancreatitis | 6 | 2023 | 97 | 0.740 |
Why?
|
| Gallbladder | 12 | 2007 | 40 | 0.700 |
Why?
|
| Patient Discharge | 3 | 2023 | 503 | 0.690 |
Why?
|
| Gallstones | 3 | 2020 | 25 | 0.690 |
Why?
|
| Aged | 66 | 2022 | 14457 | 0.690 |
Why?
|
| Male | 93 | 2022 | 29938 | 0.680 |
Why?
|
| Nomograms | 1 | 2020 | 18 | 0.660 |
Why?
|
| Vascular Fistula | 1 | 2020 | 7 | 0.650 |
Why?
|
| Pancreas | 7 | 2019 | 154 | 0.650 |
Why?
|
| Crohn Disease | 2 | 2020 | 110 | 0.640 |
Why?
|
| Patient Readmission | 7 | 2023 | 427 | 0.630 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 83 | 0.630 |
Why?
|
| Adult | 60 | 2022 | 16896 | 0.620 |
Why?
|
| Venous Thrombosis | 5 | 2022 | 112 | 0.610 |
Why?
|
| Cholangiocarcinoma | 8 | 2012 | 31 | 0.570 |
Why?
|
| Choledochostomy | 1 | 2018 | 3 | 0.560 |
Why?
|
| Common Bile Duct | 1 | 2018 | 19 | 0.560 |
Why?
|
| Duodenum | 1 | 2018 | 42 | 0.550 |
Why?
|
| Pancreatic Cyst | 6 | 2018 | 24 | 0.550 |
Why?
|
| Hepatectomy | 7 | 2022 | 63 | 0.550 |
Why?
|
| Treatment Outcome | 36 | 2023 | 5630 | 0.530 |
Why?
|
| Bile Duct Neoplasms | 7 | 2012 | 55 | 0.520 |
Why?
|
| Carcinoma, Papillary | 6 | 2019 | 37 | 0.520 |
Why?
|
| Incidence | 19 | 2022 | 1374 | 0.490 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 5468 | 0.460 |
Why?
|
| Debridement | 5 | 2022 | 33 | 0.460 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2010 | 27 | 0.440 |
Why?
|
| Palliative Care | 8 | 2017 | 235 | 0.440 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2023 | 89 | 0.440 |
Why?
|
| Length of Stay | 15 | 2021 | 807 | 0.430 |
Why?
|
| Obesity | 10 | 2022 | 1234 | 0.400 |
Why?
|
| Gastroparesis | 3 | 2019 | 8 | 0.400 |
Why?
|
| Laparotomy | 3 | 2021 | 51 | 0.390 |
Why?
|
| Gallbladder Diseases | 4 | 2007 | 27 | 0.390 |
Why?
|
| Risk Factors | 20 | 2023 | 5284 | 0.380 |
Why?
|
| Survival Rate | 16 | 2020 | 853 | 0.370 |
Why?
|
| Blood Loss, Surgical | 3 | 2018 | 65 | 0.340 |
Why?
|
| Neoplasm Invasiveness | 12 | 2018 | 279 | 0.330 |
Why?
|
| Liver Diseases | 2 | 2022 | 155 | 0.330 |
Why?
|
| Indiana | 10 | 2021 | 21 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2020 | 1641 | 0.320 |
Why?
|
| Bile | 6 | 2019 | 19 | 0.320 |
Why?
|
| Clinical Competence | 3 | 2020 | 724 | 0.310 |
Why?
|
| Surgical Wound Infection | 4 | 2023 | 117 | 0.310 |
Why?
|
| Pancreaticojejunostomy | 3 | 2017 | 5 | 0.310 |
Why?
|
| Sphincterotomy, Transduodenal | 3 | 2023 | 4 | 0.310 |
Why?
|
| Leptin | 8 | 2006 | 86 | 0.310 |
Why?
|
| Insulin Resistance | 3 | 2007 | 412 | 0.300 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 277 | 0.290 |
Why?
|
| Cholelithiasis | 4 | 2004 | 23 | 0.290 |
Why?
|
| Muscle, Smooth | 3 | 2019 | 134 | 0.290 |
Why?
|
| Gastrostomy | 3 | 2019 | 29 | 0.280 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2010 | 12 | 0.280 |
Why?
|
| Biliary Fistula | 2 | 2020 | 4 | 0.280 |
Why?
|
| Prognosis | 12 | 2020 | 1744 | 0.270 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 2464 | 0.270 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2023 | 47 | 0.260 |
Why?
|
| Prospective Studies | 12 | 2023 | 3296 | 0.260 |
Why?
|
| Splenic Artery | 2 | 2020 | 9 | 0.250 |
Why?
|
| Postoperative Care | 3 | 2018 | 123 | 0.250 |
Why?
|
| Preoperative Care | 7 | 2017 | 194 | 0.250 |
Why?
|
| Gallbladder Neoplasms | 1 | 2006 | 16 | 0.250 |
Why?
|
| Hernia, Ventral | 2 | 2020 | 25 | 0.250 |
Why?
|
| Splenectomy | 2 | 2019 | 41 | 0.240 |
Why?
|
| Gallbladder Emptying | 5 | 2006 | 5 | 0.240 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 22 | 0.240 |
Why?
|
| Necrosis | 6 | 2022 | 145 | 0.220 |
Why?
|
| Logistic Models | 6 | 2020 | 1267 | 0.220 |
Why?
|
| Intestinal Obstruction | 2 | 2020 | 53 | 0.220 |
Why?
|
| Cholesterol | 8 | 2007 | 259 | 0.220 |
Why?
|
| Aneurysm, False | 2 | 2020 | 50 | 0.220 |
Why?
|
| Insulin | 3 | 2006 | 686 | 0.210 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2023 | 12 | 0.200 |
Why?
|
| Surgical Wound | 1 | 2023 | 10 | 0.200 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2002 | 9 | 0.190 |
Why?
|
| Analgesia | 1 | 2022 | 31 | 0.190 |
Why?
|
| Cholangitis | 2 | 2019 | 11 | 0.190 |
Why?
|
| Pancreatitis, Chronic | 3 | 2020 | 19 | 0.190 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 162 | 0.190 |
Why?
|
| Dilatation, Pathologic | 2 | 2019 | 31 | 0.190 |
Why?
|
| Young Adult | 11 | 2020 | 4713 | 0.190 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 518 | 0.190 |
Why?
|
| Cystadenoma, Mucinous | 2 | 2017 | 5 | 0.180 |
Why?
|
| Colonic Diseases | 1 | 2022 | 34 | 0.180 |
Why?
|
| Hyperamylasemia | 1 | 2021 | 1 | 0.180 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2014 | 10 | 0.170 |
Why?
|
| Disease Progression | 4 | 2022 | 1170 | 0.170 |
Why?
|
| Patient Selection | 7 | 2019 | 486 | 0.170 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 8 | 0.170 |
Why?
|
| Adolescent | 10 | 2020 | 6258 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2020 | 805 | 0.170 |
Why?
|
| Portal Vein | 2 | 2022 | 38 | 0.170 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 7 | 0.170 |
Why?
|
| Surgical Mesh | 1 | 2020 | 58 | 0.160 |
Why?
|
| Pulmonary Embolism | 2 | 2020 | 173 | 0.160 |
Why?
|
| Gastrectomy | 1 | 2020 | 41 | 0.160 |
Why?
|
| Wound Closure Techniques | 1 | 2020 | 6 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2022 | 182 | 0.160 |
Why?
|
| Leukocytosis | 1 | 2019 | 15 | 0.160 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2019 | 12 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 791 | 0.160 |
Why?
|
| Amylases | 2 | 2021 | 12 | 0.160 |
Why?
|
| Peritoneal Lavage | 1 | 2019 | 4 | 0.160 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2023 | 7 | 0.160 |
Why?
|
| Emergencies | 1 | 2020 | 120 | 0.150 |
Why?
|
| Nurse's Role | 1 | 2020 | 120 | 0.150 |
Why?
|
| Activins | 1 | 2019 | 54 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 79 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 178 | 0.150 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 208 | 0.150 |
Why?
|
| Lipase | 2 | 2021 | 50 | 0.150 |
Why?
|
| Constriction, Pathologic | 4 | 2020 | 126 | 0.150 |
Why?
|
| Analgesia, Epidural | 1 | 2019 | 27 | 0.150 |
Why?
|
| Time Factors | 9 | 2019 | 3710 | 0.150 |
Why?
|
| Stomach | 1 | 2019 | 88 | 0.150 |
Why?
|
| Deoxycytidine | 2 | 2017 | 42 | 0.150 |
Why?
|
| Workload | 1 | 2019 | 127 | 0.150 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 14 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2019 | 22 | 0.150 |
Why?
|
| Cholecystokinin | 4 | 2006 | 9 | 0.150 |
Why?
|
| DNA Fingerprinting | 1 | 2018 | 8 | 0.150 |
Why?
|
| Dietary Carbohydrates | 3 | 2007 | 61 | 0.150 |
Why?
|
| Travel | 1 | 2018 | 42 | 0.150 |
Why?
|
| Clostridium Infections | 1 | 2019 | 49 | 0.150 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 37 | 0.150 |
Why?
|
| Enteral Nutrition | 2 | 2019 | 54 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 705 | 0.140 |
Why?
|
| Cholecystectomy | 3 | 2007 | 34 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 58 | 0.140 |
Why?
|
| Gastric Bypass | 1 | 2019 | 76 | 0.140 |
Why?
|
| Surgeons | 1 | 2021 | 181 | 0.140 |
Why?
|
| Survival Analysis | 6 | 2015 | 584 | 0.140 |
Why?
|
| Thrombosis | 1 | 2020 | 198 | 0.140 |
Why?
|
| Cholestasis | 2 | 1996 | 66 | 0.140 |
Why?
|
| Choledocholithiasis | 1 | 2018 | 5 | 0.140 |
Why?
|
| Analgesics | 1 | 2019 | 102 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2019 | 85 | 0.140 |
Why?
|
| Cross Infection | 1 | 2019 | 164 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2020 | 311 | 0.140 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 53 | 0.140 |
Why?
|
| Medical History Taking | 1 | 2017 | 68 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 301 | 0.140 |
Why?
|
| Cholecystitis | 2 | 2007 | 30 | 0.130 |
Why?
|
| Hepatic Duct, Common | 1 | 2017 | 7 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 346 | 0.130 |
Why?
|
| Jejunum | 1 | 2017 | 14 | 0.130 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 33 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 146 | 0.130 |
Why?
|
| Patient Care Team | 2 | 2017 | 340 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2018 | 101 | 0.130 |
Why?
|
| Cancer Pain | 1 | 2017 | 16 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1999 | 33 | 0.130 |
Why?
|
| Patient Safety | 1 | 2019 | 243 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 173 | 0.130 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 35 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 42 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 2 | 2015 | 42 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 323 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2017 | 64 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 69 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 476 | 0.130 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 981 | 0.120 |
Why?
|
| Blood Glucose | 7 | 2007 | 484 | 0.120 |
Why?
|
| Inpatients | 1 | 2018 | 304 | 0.120 |
Why?
|
| Sphincter of Oddi | 3 | 2019 | 4 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 32 | 0.120 |
Why?
|
| Databases, Factual | 5 | 2018 | 846 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 107 | 0.120 |
Why?
|
| Lipoma | 1 | 2015 | 18 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 769 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2015 | 9 | 0.120 |
Why?
|
| Financing, Organized | 1 | 2015 | 16 | 0.120 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 507 | 0.120 |
Why?
|
| Surgical Stapling | 1 | 2015 | 11 | 0.120 |
Why?
|
| Anti-Ulcer Agents | 1 | 2015 | 9 | 0.110 |
Why?
|
| Intubation, Gastrointestinal | 3 | 2021 | 21 | 0.110 |
Why?
|
| Publications | 1 | 2015 | 29 | 0.110 |
Why?
|
| CA-19-9 Antigen | 3 | 2014 | 10 | 0.110 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 1995 | 5 | 0.110 |
Why?
|
| Peptic Ulcer | 1 | 2015 | 20 | 0.110 |
Why?
|
| Splenic Vein | 1 | 2014 | 2 | 0.110 |
Why?
|
| Ampulla of Vater | 1 | 1995 | 12 | 0.110 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 35 | 0.110 |
Why?
|
| Lymph Node Excision | 2 | 2006 | 46 | 0.110 |
Why?
|
| Cystadenoma, Serous | 2 | 2005 | 4 | 0.110 |
Why?
|
| Adenoma | 1 | 2014 | 70 | 0.110 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2014 | 1 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 4 | 0.110 |
Why?
|
| Lipids | 2 | 2007 | 315 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 229 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 174 | 0.100 |
Why?
|
| Parasympatholytics | 1 | 2013 | 7 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 566 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 19 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2020 | 483 | 0.100 |
Why?
|
| Mutation | 2 | 2019 | 2615 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 719 | 0.100 |
Why?
|
| Faculty, Medical | 1 | 2015 | 196 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 1092 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 71 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2015 | 155 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2012 | 25 | 0.100 |
Why?
|
| Deep Sedation | 1 | 2012 | 4 | 0.090 |
Why?
|
| Animals | 18 | 2019 | 20716 | 0.090 |
Why?
|
| Body Weight | 7 | 2007 | 379 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2019 | 868 | 0.090 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 243 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 448 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 863 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 10 | 2007 | 3402 | 0.090 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2012 | 41 | 0.090 |
Why?
|
| Liver | 3 | 2012 | 860 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 662 | 0.090 |
Why?
|
| Nitric Oxide Synthase | 2 | 2001 | 47 | 0.090 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2001 | 22 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2019 | 411 | 0.090 |
Why?
|
| Reoperation | 3 | 2019 | 288 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 88 | 0.090 |
Why?
|
| Crystallization | 6 | 2007 | 99 | 0.080 |
Why?
|
| Mice | 13 | 2019 | 10864 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1151 | 0.080 |
Why?
|
| Anastomosis, Surgical | 3 | 2020 | 115 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2020 | 201 | 0.080 |
Why?
|
| Dietary Fats | 2 | 2007 | 174 | 0.080 |
Why?
|
| Robotics | 1 | 2010 | 86 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 136 | 0.080 |
Why?
|
| Endosonography | 3 | 2017 | 26 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 18 | 0.070 |
Why?
|
| Bile Ducts, Extrahepatic | 2 | 2006 | 3 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 375 | 0.070 |
Why?
|
| Operative Time | 2 | 2019 | 91 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2007 | 220 | 0.070 |
Why?
|
| Cholesterol, Dietary | 2 | 2006 | 29 | 0.070 |
Why?
|
| Adipose Tissue | 2 | 2007 | 295 | 0.070 |
Why?
|
| Risk Assessment | 5 | 2019 | 2027 | 0.070 |
Why?
|
| Cholangitis, Sclerosing | 2 | 1999 | 13 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2007 | 43 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 728 | 0.070 |
Why?
|
| Morbidity | 2 | 2020 | 112 | 0.070 |
Why?
|
| Azetidines | 1 | 2007 | 8 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2007 | 35 | 0.070 |
Why?
|
| Statistics, Nonparametric | 4 | 2009 | 215 | 0.070 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2007 | 2 | 0.070 |
Why?
|
| Resistin | 1 | 2007 | 6 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2019 | 345 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 931 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 33 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2019 | 397 | 0.060 |
Why?
|
| Midwestern United States | 1 | 2006 | 25 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 50 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 363 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2021 | 867 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 67 | 0.060 |
Why?
|
| Gene Expression | 2 | 2019 | 843 | 0.060 |
Why?
|
| United States | 4 | 2020 | 7837 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 26 | 0.060 |
Why?
|
| Mice, Obese | 4 | 2006 | 80 | 0.060 |
Why?
|
| Dissection | 1 | 2005 | 48 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 323 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1120 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2005 | 80 | 0.050 |
Why?
|
| Cystadenoma | 1 | 2004 | 7 | 0.050 |
Why?
|
| Pylorus | 1 | 2004 | 10 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 220 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 2184 | 0.050 |
Why?
|
| Acetylcholine | 4 | 2006 | 44 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2011 | 2572 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 61 | 0.050 |
Why?
|
| Adenoma, Islet Cell | 1 | 2003 | 4 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2017 | 68 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 89 | 0.050 |
Why?
|
| Recurrence | 3 | 2014 | 641 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 1553 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 523 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 124 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 44 | 0.050 |
Why?
|
| Stents | 1 | 2007 | 489 | 0.050 |
Why?
|
| Muscle Contraction | 2 | 2019 | 202 | 0.050 |
Why?
|
| Diet | 1 | 2006 | 527 | 0.050 |
Why?
|
| Acute Disease | 1 | 2023 | 669 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 541 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1406 | 0.040 |
Why?
|
| Ileum | 1 | 2001 | 21 | 0.040 |
Why?
|
| Decompression | 1 | 2021 | 1 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2021 | 6 | 0.040 |
Why?
|
| Organ Size | 3 | 2007 | 170 | 0.040 |
Why?
|
| North America | 2 | 2012 | 111 | 0.040 |
Why?
|
| Gastric Fistula | 1 | 2020 | 4 | 0.040 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2020 | 7 | 0.040 |
Why?
|
| Splanchnic Circulation | 1 | 2020 | 16 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 160 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 25 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 36 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 417 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 897 | 0.040 |
Why?
|
| Genotype | 1 | 2002 | 664 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 105 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 70 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Triglycerides | 3 | 2007 | 245 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 45 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 99 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 760 | 0.040 |
Why?
|
| Efficiency | 1 | 2019 | 41 | 0.040 |
Why?
|
| Cachexia | 1 | 2019 | 9 | 0.040 |
Why?
|
| Activin Receptors, Type II | 1 | 2019 | 9 | 0.040 |
Why?
|
| Heparin | 1 | 2020 | 116 | 0.040 |
Why?
|
| Colectomy | 1 | 2020 | 109 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 163 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 33 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 180 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 38 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1999 | 17 | 0.040 |
Why?
|
| Lymphoma | 1 | 2000 | 104 | 0.040 |
Why?
|
| Muscular Atrophy | 1 | 2019 | 26 | 0.040 |
Why?
|
| Failure to Thrive | 1 | 2019 | 8 | 0.040 |
Why?
|
| Centralized Hospital Services | 1 | 2018 | 6 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 112 | 0.040 |
Why?
|
| Genes, ras | 1 | 1998 | 27 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 332 | 0.040 |
Why?
|
| Genes, p53 | 1 | 1998 | 51 | 0.040 |
Why?
|
| Nurses | 1 | 2020 | 109 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 280 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2019 | 94 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 65 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 33 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 1241 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1561 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 170 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 493 | 0.040 |
Why?
|
| Progesterone | 1 | 1999 | 163 | 0.040 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2017 | 2 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2017 | 5 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 134 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2020 | 154 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2020 | 487 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2017 | 20 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 2017 | 26 | 0.030 |
Why?
|
| Anoctamin-1 | 1 | 2017 | 16 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 91 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 162 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 97 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 738 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 232 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 536 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2017 | 13 | 0.030 |
Why?
|
| Failure to Rescue, Health Care | 1 | 2017 | 5 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 112 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2196 | 0.030 |
Why?
|
| Random Allocation | 2 | 2012 | 199 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2007 | 56 | 0.030 |
Why?
|
| Phospholipids | 2 | 2007 | 82 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 455 | 0.030 |
Why?
|
| Choledochal Cyst | 1 | 1996 | 3 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 281 | 0.030 |
Why?
|
| Universities | 1 | 2017 | 161 | 0.030 |
Why?
|
| Dogs | 2 | 2012 | 330 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 519 | 0.030 |
Why?
|
| Surgery Department, Hospital | 1 | 2015 | 20 | 0.030 |
Why?
|
| Neuropeptide Y | 2 | 2006 | 13 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2017 | 180 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 1470 | 0.030 |
Why?
|
| Jejunostomy | 2 | 2010 | 7 | 0.030 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 16 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 46 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 119 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 60 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1360 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 6 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2014 | 41 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 99 | 0.030 |
Why?
|
| Neurotransmitter Agents | 2 | 2004 | 42 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 78 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2004 | 153 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 443 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2006 | 410 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 192 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1535 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 1665 | 0.020 |
Why?
|
| Sciuridae | 2 | 2001 | 3 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 775 | 0.020 |
Why?
|
| Ligation | 1 | 2011 | 39 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 721 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 921 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 215 | 0.020 |
Why?
|
| Algorithms | 2 | 2010 | 1005 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2001 | 317 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 128 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 66 | 0.020 |
Why?
|
| Florida | 1 | 2010 | 47 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2001 | 612 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 570 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 606 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 52 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3033 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 315 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 312 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2009 | 137 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cholesterol Esters | 1 | 2007 | 10 | 0.020 |
Why?
|
| Poverty | 1 | 2010 | 298 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 72 | 0.020 |
Why?
|
| Viscera | 1 | 2007 | 10 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 61 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 88 | 0.020 |
Why?
|
| Cholinergic Agents | 1 | 2006 | 8 | 0.020 |
Why?
|
| Decision Making | 1 | 2010 | 411 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1115 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 151 | 0.020 |
Why?
|
| Butter | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 79 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 190 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 2005 | 18 | 0.010 |
Why?
|
| Enema | 1 | 2005 | 14 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 302 | 0.010 |
Why?
|
| Spleen | 1 | 2005 | 483 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 1208 | 0.010 |
Why?
|
| Vacuoles | 1 | 2003 | 26 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 934 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2003 | 106 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 866 | 0.010 |
Why?
|
| Contrast Media | 1 | 2005 | 422 | 0.010 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide | 1 | 2001 | 1 | 0.010 |
Why?
|
| Nitroarginine | 1 | 2001 | 2 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2001 | 17 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2001 | 7 | 0.010 |
Why?
|
| Iron, Dietary | 1 | 2001 | 9 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2001 | 139 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2001 | 46 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2001 | 135 | 0.010 |
Why?
|
| Vincristine | 1 | 2000 | 28 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 87 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 85 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 103 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 68 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 622 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 373 | 0.010 |
Why?
|
| West Virginia | 1 | 1998 | 6 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 221 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 408 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1999 | 102 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 1999 | 216 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 308 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 265 | 0.010 |
Why?
|
| Child | 1 | 1999 | 4541 | 0.000 |
Why?
|